The Experts below are selected from a list of 6 Experts worldwide ranked by ideXlab platform
Stephen J. Marx - One of the best experts on this subject based on the ideXlab platform.
-
Recent Topics Around Multiple Endocrine Neoplasia Type 1
2018Co-Authors: Stephen J. MarxAbstract:Introduction Multiple endocrine neoplasia type 1 (MEN1) is complex with regard to clinical expressions, management, and molecular pathways. Advances are being made broadly and in focused aspects. Selected topics are presented for their developments since publication of the most recent MEN1 consensus guidelines 6 years ago. Methods Topics were selected for clinical impact or broad interest or both. For each topic, information was obtained from original reports and reviews. Results The selected topics are as follows: Tumor behavior and breast cancer in MEN1; foregut Neuroectoderm Tumor screening, biomarkers periodically to detect Tumor emergence of foregut Neuroectoderm Tumors, 68Ga dotatate positron emission tomography/computed tomography for pancreatic and duodenal Neuroectodermal Tumor imaging, and glucagon-like peptide-1 receptor scintigraphy for insulinoma; therapy, the size of pancreatic neuroendocrine Tumor (NET) as one criterion for surgery, minimally invasive surgery of pancreatic NETs, and 177Lu dotatate therapy; MEN1 gene, the search for the MEN1/menin pathway and MEN1 or GCM2 mutation in familial isolated hyperparathyroidism, and MEN1 mutation-positive vs mutation-negative cases of MEN1 are different. Conclusions MEN1 topics are a rich and fast-moving area. Important highlights stand out, and major and rapid advances will continue into the near future.
Eurocare Working Group - One of the best experts on this subject based on the ideXlab platform.
-
Survival of European patients with central nervous system Tumors.
2012Co-Authors: Sant Milena, Minicozzi Pamela, Lagorio Susanna, Børge Johannesen Tom, Marcos-gragera Rafael, Francisci Silvia, Eurocare Working GroupAbstract:We present estimates of population-based 5-year relative survival for adult Europeans diagnosed with central nervous system Tumors, by morphology (14 categories based on cell lineage and malignancy grade), sex, age at diagnosis and region (UK and Ireland, Northern, Central, Eastern and Southern Europe) for the most recent period with available data (2000-2002). Sources were 39 EUROCARE cancer registries with continuous data from 1996 to 2002. Survival time trends (1988 to 2002) were estimated from 24 cancer registries with continuous data from 1988. Overall 5-year relative survival was 85.0% for benign, 19.9% for malignant Tumors. Benign Tumor survival ranged from 90.6% (Northern Europe) to 77.4% (UK and Ireland); for malignant Tumors the range was 25.1% (Northern Europe) to 15.6% (UK and Ireland). Survival decreased with age at diagnosis and was slightly better for women (malignant Tumors only). For glial Tumors, survival varied from 83.5% (ependymoma and choroid plexus) to 2.7% (glioblastoma); and for non-glioma Tumors from 96.5% (neurinoma) to 44.9% (primitive Neuroectoderm Tumor/medulloblastoma). Survival differences between regions narrowed after adjustment for morphology and age, and were mainly attributable to differences in morphology mix; however UK and Ireland and Eastern Europe patients still had 40% and 30% higher excess risk of death, respectively, than Northern Europe patients (reference). Survival for benign Tumors increased from 69.3% (1988-1990) to 77.1% (2000-2002); but survival for malignant Tumors did not improve indicating no useful advances in treatment over the 14-year study period, notwithstanding major improvement in the diagnosis and treatment of other solid cancers
Sant Milena - One of the best experts on this subject based on the ideXlab platform.
-
Survival of European patients with central nervous system Tumors.
2012Co-Authors: Sant Milena, Minicozzi Pamela, Lagorio Susanna, Børge Johannesen Tom, Marcos-gragera Rafael, Francisci Silvia, Eurocare Working GroupAbstract:We present estimates of population-based 5-year relative survival for adult Europeans diagnosed with central nervous system Tumors, by morphology (14 categories based on cell lineage and malignancy grade), sex, age at diagnosis and region (UK and Ireland, Northern, Central, Eastern and Southern Europe) for the most recent period with available data (2000-2002). Sources were 39 EUROCARE cancer registries with continuous data from 1996 to 2002. Survival time trends (1988 to 2002) were estimated from 24 cancer registries with continuous data from 1988. Overall 5-year relative survival was 85.0% for benign, 19.9% for malignant Tumors. Benign Tumor survival ranged from 90.6% (Northern Europe) to 77.4% (UK and Ireland); for malignant Tumors the range was 25.1% (Northern Europe) to 15.6% (UK and Ireland). Survival decreased with age at diagnosis and was slightly better for women (malignant Tumors only). For glial Tumors, survival varied from 83.5% (ependymoma and choroid plexus) to 2.7% (glioblastoma); and for non-glioma Tumors from 96.5% (neurinoma) to 44.9% (primitive Neuroectoderm Tumor/medulloblastoma). Survival differences between regions narrowed after adjustment for morphology and age, and were mainly attributable to differences in morphology mix; however UK and Ireland and Eastern Europe patients still had 40% and 30% higher excess risk of death, respectively, than Northern Europe patients (reference). Survival for benign Tumors increased from 69.3% (1988-1990) to 77.1% (2000-2002); but survival for malignant Tumors did not improve indicating no useful advances in treatment over the 14-year study period, notwithstanding major improvement in the diagnosis and treatment of other solid cancers
Minicozzi Pamela - One of the best experts on this subject based on the ideXlab platform.
-
Survival of European patients with central nervous system Tumors.
2012Co-Authors: Sant Milena, Minicozzi Pamela, Lagorio Susanna, Børge Johannesen Tom, Marcos-gragera Rafael, Francisci Silvia, Eurocare Working GroupAbstract:We present estimates of population-based 5-year relative survival for adult Europeans diagnosed with central nervous system Tumors, by morphology (14 categories based on cell lineage and malignancy grade), sex, age at diagnosis and region (UK and Ireland, Northern, Central, Eastern and Southern Europe) for the most recent period with available data (2000-2002). Sources were 39 EUROCARE cancer registries with continuous data from 1996 to 2002. Survival time trends (1988 to 2002) were estimated from 24 cancer registries with continuous data from 1988. Overall 5-year relative survival was 85.0% for benign, 19.9% for malignant Tumors. Benign Tumor survival ranged from 90.6% (Northern Europe) to 77.4% (UK and Ireland); for malignant Tumors the range was 25.1% (Northern Europe) to 15.6% (UK and Ireland). Survival decreased with age at diagnosis and was slightly better for women (malignant Tumors only). For glial Tumors, survival varied from 83.5% (ependymoma and choroid plexus) to 2.7% (glioblastoma); and for non-glioma Tumors from 96.5% (neurinoma) to 44.9% (primitive Neuroectoderm Tumor/medulloblastoma). Survival differences between regions narrowed after adjustment for morphology and age, and were mainly attributable to differences in morphology mix; however UK and Ireland and Eastern Europe patients still had 40% and 30% higher excess risk of death, respectively, than Northern Europe patients (reference). Survival for benign Tumors increased from 69.3% (1988-1990) to 77.1% (2000-2002); but survival for malignant Tumors did not improve indicating no useful advances in treatment over the 14-year study period, notwithstanding major improvement in the diagnosis and treatment of other solid cancers
Lagorio Susanna - One of the best experts on this subject based on the ideXlab platform.
-
Survival of European patients with central nervous system Tumors.
2012Co-Authors: Sant Milena, Minicozzi Pamela, Lagorio Susanna, Børge Johannesen Tom, Marcos-gragera Rafael, Francisci Silvia, Eurocare Working GroupAbstract:We present estimates of population-based 5-year relative survival for adult Europeans diagnosed with central nervous system Tumors, by morphology (14 categories based on cell lineage and malignancy grade), sex, age at diagnosis and region (UK and Ireland, Northern, Central, Eastern and Southern Europe) for the most recent period with available data (2000-2002). Sources were 39 EUROCARE cancer registries with continuous data from 1996 to 2002. Survival time trends (1988 to 2002) were estimated from 24 cancer registries with continuous data from 1988. Overall 5-year relative survival was 85.0% for benign, 19.9% for malignant Tumors. Benign Tumor survival ranged from 90.6% (Northern Europe) to 77.4% (UK and Ireland); for malignant Tumors the range was 25.1% (Northern Europe) to 15.6% (UK and Ireland). Survival decreased with age at diagnosis and was slightly better for women (malignant Tumors only). For glial Tumors, survival varied from 83.5% (ependymoma and choroid plexus) to 2.7% (glioblastoma); and for non-glioma Tumors from 96.5% (neurinoma) to 44.9% (primitive Neuroectoderm Tumor/medulloblastoma). Survival differences between regions narrowed after adjustment for morphology and age, and were mainly attributable to differences in morphology mix; however UK and Ireland and Eastern Europe patients still had 40% and 30% higher excess risk of death, respectively, than Northern Europe patients (reference). Survival for benign Tumors increased from 69.3% (1988-1990) to 77.1% (2000-2002); but survival for malignant Tumors did not improve indicating no useful advances in treatment over the 14-year study period, notwithstanding major improvement in the diagnosis and treatment of other solid cancers